Floxuridine injection
Products billed under this code include Floxuridine.
Payment limit per 500 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Floxuridine.
Payment limit per 500 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Floxuridine | JND Therapeutics | 81643-9270-01 | 1 | $4,389.848 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $4,389.848 | −$6.644 | 500 MG | Floxuridine injection | v1, posted September 17, 2026 |
| 3Q26 | $4,396.492 | +$145.525 | 500 MG | Floxuridine injection | v1, posted September 15, 2026 |
| 2Q26 | $4,250.967 | −$3.956 | 500 MG | Floxuridine injection | v1, posted September 15, 2026 |
| 1Q26 | $4,254.923 | +$126.904 | 500 MG | Floxuridine injection | v1, posted September 15, 2026 |
| 4Q25 | $4,128.019 | +$2.469 | 500 MG | Floxuridine injection | v1, posted September 8, 2026 |
| 3Q25 | $4,125.55 | +$137.217 | 500 MG | Floxuridine injection | v1, posted March 10, 2026 |
| 2Q25 | $3,988.333 | −$1.307 | 500 MG | Floxuridine injection | v1, posted March 10, 2026 |
| 1Q25 | $3,989.64 | +$131.609 | 500 MG | Floxuridine injection | v1, posted December 19, 2025 |
| 4Q24 | $3,858.031 | +$0.91 | 500 MG | Floxuridine injection | v1, posted June 11, 2025 |
| 3Q24 | $3,857.121 | +$128.571 | 500 MG | Floxuridine injection | v1, posted June 11, 2025 |
| 2Q24 | $3,728.55 | +$6.511 | 500 MG | Floxuridine injection | v1, posted March 11, 2025 |
| 1Q24 | $3,722.039 | +$171.039 | 500 MG | Floxuridine injection | v1, posted December 19, 2024 |
| 4Q23 | $3,551.00 | $0.00 | 500 MG | Floxuridine injection | v1, posted October 10, 2024 |
| 3Q23 | $3,551.00 | +$37.437 | 500 MG | Floxuridine injection | v1, posted June 5, 2024 |
| 2Q23 | $3,513.563 | +$623.395 | 500 MG | Floxuridine injection | v1, posted February 23, 2024 |
| 1Q23 | $2,890.168 | +$2,800.486 | 500 MG | Floxuridine injection | v1, posted December 6, 2023 |
| 4Q22 | $89.682 | −$7.627 | 500 MG | Floxuridine injection | v1, posted June 22, 2023 |
| 3Q22 | $97.309 | −$0.115 | 500 MG | Floxuridine injection | v1, posted June 9, 2023 |
| 2Q22 | $97.424 | +$27.534 | 500 MG | Floxuridine injection | v1, posted December 14, 2022 |
| 1Q22 | $69.89 | −$4.441 | 500 MG | Floxuridine injection | v1, posted June 8, 2022 |
| 4Q21 | $74.331 | +$15.223 | 500 MG | Floxuridine injection | v1, posted June 2, 2022 |
| 3Q21 | $59.108 | −$4.662 | 500 MG | Floxuridine injection | v1, posted June 2, 2022 |
| 2Q21 | $63.77 | −$6.356 | 500 MG | Floxuridine injection | v1, posted March 1, 2022 |
| 1Q21 | $70.126 | – | 500 MG | Floxuridine injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.